Concert Pharmaceuticals, Inc.
CNCE
CNCE was delisted on the 3rd of March, 2023.
79 hedge funds and large institutions have $175M invested in Concert Pharmaceuticals, Inc. in 2020 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 35 increasing their positions, 27 reducing their positions, and 8 closing their positions.
30% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 27
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
20% more capital invested
Capital invested by funds: $145M → $175M (+$29.8M)
3% more funds holding
Funds holding: 77 → 79 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$18.3M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$8.61M |
| 3 |
Millennium Management
New York
|
+$6.99M |
| 4 |
BlackRock
New York
|
+$2.43M |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$1.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$1.68M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$830K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$455K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$448K |
| 5 |
Morgan Stanley
New York
|
-$436K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | -$12.4K | -1,262 | -91% |
|
|
AWM
77
AllSquare Wealth Management
Albany,
New York
| $1K | – | – | – |
|
|
AIC
78
Ameritas Investment Company
Lincoln,
Nebraska
| $1K | +$956 | +97 | New |
|
|
BWA
79
BDO Wealth Advisors
Jacksonville,
Florida
| $1K | +$986 | +100 | New |
|
|
GCP
80
GSA Capital Partners
London,
United Kingdom
| – | -$448K | -48,565 | Closed |
|
|
OAM
81
Oxford Asset Management
Oxford,
United Kingdom
| – | -$187K | -20,269 | Closed |
|
|
HF
82
HRT Financial
New York
| – | -$153K | -16,627 | Closed |
|
83
AQR Capital Management
Greenwich,
Connecticut
| – | -$126K | -13,648 | Closed |
|
|
RJA
84
Raymond James & Associates
St Petersburg,
Florida
| – | -$102K | -11,073 | Closed |
|
85
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$25K | -2,697 | Closed |
|
|
PCM
86
Prelude Capital Management
New York
| – | -$24K | -2,584 | Closed |
|
|
TRCT
87
Tower Research Capital (TRC)
New York
| – | -$4K | -409 | Closed |
|
CNCE Hedge Fund Activity: Q1 2020 in Review
79 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q1 2020, worth a combined $175M — up 20% from $145M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CNCE positions and 8 closed out — a net gain of 2 holders — while 35 added to existing stakes and 27 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $18.3M. The largest seller was Panagora Asset Management, cutting an estimated $1.68M.
- 79 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q1 2020, up from 77 in Q4 2019.
- Funds reported $175M of Concert Pharmaceuticals, Inc. stock for Q1 2020, up 20% quarter-over-quarter.
- 10 funds opened new Concert Pharmaceuticals, Inc. positions in Q1 2020 and 8 closed out, a net change of +2 holders.
- The largest Concert Pharmaceuticals, Inc. buyer in Q1 2020 was RA Capital Management, an estimated $18.3M added.
- The largest Concert Pharmaceuticals, Inc. seller in Q1 2020 was Panagora Asset Management, an estimated $1.68M sold.
Based on aggregated 13F filings for Q1 2020.